Contact

Our Science

Engineering resistance to tumor suppression.

Solid tumors use multiple pathways to shut down CAR-T cells. We combine protections within the same cell to help it keep working.

Conceptual illustration of a blue T cell receiving several suppressive signals from the surrounding GBM tumor environment.

Why activity fades

Even healthy-donor T cells need protection.

GBM shuts them down through overlapping signals.

Block one signal, others remain.
Conceptual illustration of a blue engineered T cell wearing KiraGen headphones in the same GBM tumor environment, representing resistance to multiple suppressive signals.

KiraGen’s approach

Noise cancellation for cell therapy.

Combinations of coordinated gene edits. Designed to resist multiple tumor shutdown signals.

Engineering strategies compared

Conceptual comparison of engineering strategies. Linked publications are external research, not head-to-head comparisons or KGEN-001 results. Sustained activity is a design objective, not an established clinical outcome for KGEN-001.

See the KGEN-001 design

Why now

Patient evidence informs the design.
Multiplex editing makes it testable.

Blood cancers · 2025 publication

Combine protections in one cell

Base-edited donor CAR-T cells have induced remissions in T-cell leukemia, allowing nine patients to proceed to stem-cell transplantation.

Chiesa et al., NEJM

Recurrent GBM · 2025 announcement

Build on donor-cell clinical development

T-Maximum announced FDA clearance to initiate a Phase 2 trial of donor-derived MT027 in recurrent glioblastoma.

T-Maximum announcement

Human GBM · 2026 publication

Match protection to tumor biology

Analysis of a recurrent GBM CAR-T trial linked suppressive immune-cell populations with poorer outcomes, helping define barriers to address.

Freeburg et al., Cell

External clinical and biological precedents, not KGEN-001 results.

Focus + transfer

Focused now. Built to transfer.

Reuse the engineering foundation. Match protection to each tumor.

Externally funded pilots

DMG / DIPG exploratory pilot represented by an engineered cell.

DMG / DIPG

CNS extension

Grant-supported
Liposarcoma exploratory pilot represented by an engineered cell.

Liposarcoma

Dedifferentiated liposarcoma

Partner-funded pilot underway

Our lead program establishes the GBM reference. The pilots test which protections carry into other tumor settings.

How KiraLOGIC guides the next designs